{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesotheliomas&page=3",
    "query": {
      "condition": "Mesotheliomas",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 338,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesotheliomas&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesotheliomas&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T03:08:05.720Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03867578",
      "title": "Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mesothelioma",
        "Peritoneal Mesothelioma"
      ],
      "interventions": [
        {
          "name": "HR-MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Standard CT Imaging",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Ultrasound",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-10-10",
      "completion_date": "2022-07-20",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867578"
    },
    {
      "nct_id": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non-small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Carcinoma",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM831",
          "type": "DRUG"
        },
        {
          "name": "NGM831 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-31",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05215574"
    },
    {
      "nct_id": "NCT04840615",
      "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "LMB-100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT CAP",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-06-11",
      "completion_date": "2022-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840615"
    },
    {
      "nct_id": "NCT04914897",
      "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pleural Mesothelioma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "THOR-707",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2021-09-23",
      "completion_date": "2024-10-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04914897"
    },
    {
      "nct_id": "NCT05425576",
      "title": "OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "OT-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncotelic Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2025-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05425576"
    },
    {
      "nct_id": "NCT00165516",
      "title": "Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pleural Mesothelioma",
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Sodium Thiosulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2004-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2014-03-27",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165516"
    },
    {
      "nct_id": "NCT06466187",
      "title": "A Study of SGN-MesoC2 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Ovarian Neoplasms",
        "Pancreatic Adenocarcinoma",
        "Colorectal Neoplasms",
        "Mesothelioma",
        "Other Solid Tumors",
        "Endometrial"
      ],
      "interventions": [
        {
          "name": "PF-08052666",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2024-08-02",
      "completion_date": "2026-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466187"
    },
    {
      "nct_id": "NCT01655225",
      "title": "A Study of LY3023414 in Participants With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Non-Hodgkin's Lymphoma",
        "Metastatic Breast Cancer",
        "Malignant Mesothelioma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "LY3023414",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2012-07-31",
      "completion_date": "2022-02-02",
      "has_results": false,
      "last_update_posted_date": "2022-04-08",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01655225"
    },
    {
      "nct_id": "NCT02151448",
      "title": "αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface",
        "Malignant Peritoneal Mesothelioma",
        "Peritoneal Carcinomatosis"
      ],
      "interventions": [
        {
          "name": "DC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Interferon Alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "rintatolimod",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "David Bartlett",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2014-07",
      "completion_date": "2019-02-18",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151448"
    },
    {
      "nct_id": "NCT02859415",
      "title": "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Neoplasms",
        "Lung Neoplasms",
        "Mesothelioma",
        "Thymus Neoplasms",
        "Neoplasms, Germ Cell and Embryonal"
      ],
      "interventions": [
        {
          "name": "Mithramycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2019-08-08",
      "completion_date": "2021-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-10-21T03:08:05.720Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859415"
    }
  ]
}